Tissue factor pathway inhibitor is a potential modifier of bleeding risk in factor XI deficiency.

Autor: Reitsma SE; Department of Pathology and Laboratory Medicine and UNC Blood Research Center, University of North Carolina, Chapel Hill, North Carolina, USA., Holle LA; Department of Pathology and Laboratory Medicine and UNC Blood Research Center, University of North Carolina, Chapel Hill, North Carolina, USA., Bouck EG; Department of Pathology and Laboratory Medicine and UNC Blood Research Center, University of North Carolina, Chapel Hill, North Carolina, USA., Monroe DM; Department of Medicine and UNC Blood Research Center, University of North Carolina at Chapel Hill, North Carolina, USA., Mast AE; Versiti Blood Research Institute, Milwaukee, Wisconsin, USA., Burthem J; Department of Haematology, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, UK; Institute of Cancer Sciences, The University of Manchester, Manchester, UK., Bolton-Maggs PHB; Institute of Cardiovascular Sciences, The University of Manchester, Manchester, UK., Gidley GN; Institute of Cancer Sciences, The University of Manchester, Manchester, UK; Department of Haematology, St James' Hospital, Leeds Teaching Hospitals Trust, UK., Wolberg AS; Department of Pathology and Laboratory Medicine and UNC Blood Research Center, University of North Carolina, Chapel Hill, North Carolina, USA. Electronic address: alisa_wolberg@med.unc.edu.

Publikováno v: Journal of thrombosis and haemostasis : JTH [J Thromb Haemost] 2023 Mar; Vol. 21 (3), pp. 467-479. Date of Electronic Publication: 2022 Dec 22.